[Therapy of immunoglobulin light-chain amyloidosis - everything a general practitioner wants to know].
文献摘要
Introduction Current treatment of immunoglobulin light-chain (AL) amyloidosis is highly effective, achieving a hematologic response in more than 80 % of patients. Management is based on five principles: (i) Early and accurate diagnosis, as treatment is more effective when initiated at an early stage of the disease. (ii) Optimal supportive care, including psychosocial support, prevention of infectious complications, management of heart failure and renal insufficiency, and other organ-specific interventions. Ideally, care should be delivered by an experienced multidisciplinary team with expertise in AL amyloidosis in close collaboration with the patient's general practitioner. (iii) Modern combination immunochemotherapy, typically based on daratumumab, bortezomib, cyclophosphamide, and dexamethasone. Treatment doses and intervals should be continuously and flexibly adapted according to the individual patient's clinical course. The primary therapeutic goal is to achieve a sustained complete hematologic response (CR), defined by the rapid elimination of the amyloidogenic free light chain. (iv) Regular assessment of both hematologic and organ response with prompt modification of the treatment regimen if the primary hematologic treatment target is not achieved. (v) Immediate management of disease- and treatment-related life-threatening complications, including infections, cardiac decompensation and cardiac arrhythmias.